Lead Product(s) : Iron Hydroxide Adipate Tartrate
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Avia Pharma
Deal Size : Undisclosed
Deal Type : Financing
Nemysis Limited Announces Investment by Avia Pharma AB in the Capital of the Company
Details : The financing aims to fund the clinical development of IHAT (iron hydroxide adipate tartrate), which is being evaluated for the treatment of iron deficiency.
Product Name : IHAT
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
March 18, 2025
Lead Product(s) : Iron Hydroxide Adipate Tartrate
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Avia Pharma
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Iron Hydroxide Adipate Tartrate
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Nemysis
Deal Size : Undisclosed
Deal Type : Agreement
Nemysis Limited Signs with Kolinpharma SpA an IHAT Sales and Marketing Agreement
Details : Kolinpharma will market Iron Hydroxide Adipate Tartrate (IHAT), an oral iron supplement for iron deficiency, utilizing its existing sales network under the brand KIPFeR.
Product Name : KIPFeR
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
October 01, 2024
Lead Product(s) : Iron Hydroxide Adipate Tartrate
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Nemysis
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Iron Hydroxide Adipate Tartrate
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Bruno Farmaceutici
Deal Size : Undisclosed
Deal Type : Agreement
Nemysis Limited Signs IHAT Sales and Marketing Agreement
Details : Under the agreement, Bruno will use its existing sales network and relationships with relevant clinical communities to market IHAT (iron hydroxide adipate tartrate), an oral iron supplementation product, under its own brand.
Product Name : IHAT
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
May 07, 2023
Lead Product(s) : Iron Hydroxide Adipate Tartrate
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Bruno Farmaceutici
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Iron Hydroxide Adipate Tartrate
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The patent claims describe methods for producing IHAT (Iron Hydroxide Adipate Tartrate), where Generally Recognised As Safe (GRAS) organic acids, and particularly Tartaric and Adipic acids, are used to modify the ferrihydrite nanocore of ferritin.
Product Name : IHAT-02
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 05, 2021
Lead Product(s) : Iron Hydroxide Adipate Tartrate
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable